Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by A. Aroldi
Devec: A Phase Ii Study of Metronomic Chemotherapy in Elderly Non-Fit Patients With Aggressive B-Cell Lymphomas (Promoted by Fil)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Skeletal Complications After Renal Transplantation
International Journal of Artificial Organs
Medicine
Bioengineering
Biomaterials
Biomedical Engineering
Related publications
Phase Ii Fil-Ptcl13 Study of Romidepsin-Choep Followed by High-Dose Chemotherapy and Transplantation in Untreated Peripheral T-Cell Lymphomas
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Age Is Not Important in Fit Elderly Patients With Aggressive Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Non-Anthracycline Chemotherapy Associated With a Poor Outcome in Elderly Egyptian Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma
Journal of Cancer Metastasis and Treatment
High-Dose Chemotherapy With Carboplatin, Etoposide and Ifosfamide Followed by Autologous Stem Cell Rescue in Patients With Relapsed or Refractory Malignant Lymphomas: A Phase I/Ii Study
Bone Marrow Transplantation
Transplantation
Hematology
Phase II Study of Docetaxel Alternating With Cisplatin in Chemotherapy-Naïve Patients With Advanced Non-Small Cell Lung Cancer
Anti-Cancer Drugs
Cancer Research
Oncology
Pharmacology
A Phase II Study of Oral Etoposide in Elderly Patients With Small Cell Lung Cancer.
Thorax
Pulmonary
Respiratory Medicine
The Dial Study (Dual Immunomodulation in Aggressive Lymphoma): Randomized Phase 2 Trial of Varlilumab Plus Nivolumab in Relapsed/Refractory Aggressive B-Cell Lymphomas
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
A Phase 1/2 Study of Pixantrone, Etoposide, Bendamustine And, in Cd20+ Tumors, Rituximab in Patients With Relapsed Aggressive B- Or T-Cell Lymphomas-The P[r]eben Study
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Interim Report From a Phase 2 Multicenter Study of Tazemetostat, an Ezh2 Inhibitor, in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology